GlaxoSmithKline (GSK) has partnered with several companies and organisations to expedite the development of treatments for tuberculosis (TB).
Besides GSK, the consortium comprises Evotec, Johnson & Johnson, Otsuka 色界吧, the Bill & Melinda Gates Medical Research Institute and the Bill & Melinda Gates Foundation.
The collaboration aims to deliver 鈥榩an-TB鈥� drug regimens that are Phase III ready with limited to no drug resistance. Also, the therapies are expected to be safe and better-tolerated with shorter duration and more manageable usage in comparison to current treatments.
Bill & Melinda Gates Foundation global health president Trevor Mundel said: 鈥淐urrent tools are insufficient for accelerating and sustaining global progress against TB.
鈥淚nnovative partnerships, such as the PAN-TB collaboration, are聽urgently聽needed聽to develop new drugs and treatment regimens that can address TB and advance progress towards achieving global elimination TB goals.鈥�
The existing regimen for drug-sensitive TB treatments involves several drugs under six or more months of dosing. However, this regimen is not suitable for drug-resistant TB, which requires more complex regimens that commonly have side effects.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCommenting on the development of new therapies, GSK said: 鈥淭he regimens that the PAN-TB collaboration is working to develop could help transform TB care.
鈥淎 shorter and safer novel regimen that can treat TB irrespective of pre-existing drug resistance and with reduced need for drug resistance testing, could provide a significant benefit to both patients and health systems.
The consortium will find and investigate potential pan-TB regimens, through a number of Phase II efficacy studies. The partners have already commenced pre-clinical research activities.
As part of the PAN-TB collaboration, members will leverage their collective assets, resources and scientific expertise. The partners will closely work with the European Regimen Accelerator for Tuberculosis聽(ERA4TB).
